proxyvotesnow.com

Home › Companies › ADAPTIVE BIOTECHNOLOGIES CORP. › 2024-2025

ADAPTIVE BIOTECHNOLOGIES CORP. 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings. Page generated 02 October 2026.

  • 8Reported items
  • 241Asset managers
  • 873Fund votes
  • 2025-06-10Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore ADAPTIVE BIOTECHNOLOGIES CORP. in the interactive database Compare manager voting policies

How asset managers voted at the ADAPTIVE BIOTECHNOLOGIES CORP. 2024-2025 meeting

Each item below shows how the 241 asset managers that disclosed a ADAPTIVE BIOTECHNOLOGIES CORP. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of ADAPTIVE BIOTECHNOLOGIES CORP.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To approve, on a non-binding advisory basis, the compensation of our named executive officers as described in the proxy statement;

SECTION 14A SAY-ON-PAY VOTES

Meeting held 2025-06-10; no official results are on file for this meeting.

Combines 6 wordings of this item as funds reported it.

99% fund support · no official result

FOR 99%

The 229 asset managers below cast 99% of the shares they voted on this item FOR (130,880,006 for, 1,473,223 against).

FOR: 130,880,006 (98.8%)AGAINST: 1,473,223 (1.1%)ABSTAIN: 76,365 (0.1%)NOT VOTED: 77 (0.0%)
Largest asset managers voting on “To approve, on a non-binding advisory basis, the compensation of our named executive officers as described in ” at ADAPTIVE BIOTECHNOLOGIES CORP., 2024-2025
Asset managerForAgainst AbstainWithheldVote
VIKING GLOBAL INVESTORS LP29,993,7080 00For
Vanguard11,250,5810 00For
BlackRock9,958,1050 00For
Rubric Capital Management LP8,896,0740 00For
ARK ETF Trust7,553,9210 00For
Nikko Asset Management Co., Ltd.5,757,3710 00For
Columbia Threadneedle3,403,6100 00For
Voya3,288,3530 00For
Aberdeen3,280,7680 00For
Fidelity3,123,7320 00For
GEODE CAPITAL MANAGEMENT, LLC2,831,4560 00For
Victory Capital2,529,0340 00For
Iron Triangle Partners LP2,093,8970 00For
State Street2,085,3100 00For
Blue Water Life Science Advisors, LP2,002,8390 00For
Charles Schwab1,854,2850 00For
MASSACHUSETTS FINANCIAL SERVICES CO /MA/1,728,9540 00For
DRIEHAUS CAPITAL MANAGEMENT LLC1,716,7580 00For
BRAIDWELL LP1,585,5670 00For
FRED ALGER MANAGEMENT, LLC1,577,0550 00For
MFS1,528,5960 00For
Nuveen1,284,1290 00For
Aristotle Atlantic Partners, LLC1,269,7540 00For
TIAA1,265,8150 00For
ALGER FUNDS1,238,6220 00For

Showing the 25 largest of 229 asset managers. See all 229 in the interactive database.

2. To elect one Class III director nominee to serve on the board of directors of Adaptive Biotechnologies Corporation for a three-year term expiring at the 2028 annual meeting of shareholders: Chad Robins

DIRECTOR ELECTIONS

Meeting held 2025-06-10; no official results are on file for this meeting.

Combines 5 wordings of this item as funds reported it.

100% fund support · no official result

FOR 78%ABSTAIN 22%

The 69 asset managers below cast 100% of the shares they voted on this item FOR (36,865,014 for, 0 against).

FOR: 36,865,014 (77.7%)ABSTAIN: 10,568,153 (22.3%)
Largest asset managers voting on “To elect one Class III director nominee to serve on the board of directors of Adaptive Biotechnologies Corpora” at ADAPTIVE BIOTECHNOLOGIES CORP., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard10,956,3860 00For
ARK ETF Trust7,553,9210 00For
BlackRock5,227,4590 00For
Columbia Threadneedle3,403,6100 00For
Fidelity2,563,4970 274,7860For
Aberdeen00 1,640,3840Abstain
MFS1,528,5960 00For
Voya00 1,347,9680Abstain
TIAA1,265,8150 00For
ALGER FUNDS00 1,238,6220Abstain
Bridge Builder Trust54,5410 895,0600Abstain
Charles Schwab926,8400 00For
Aristotle Funds Series Trust00 792,9750Abstain
Goldman Sachs745,8530 00For
First Trust00 724,0910Abstain
Victory Capital00 689,2870Abstain
OPTIMUM FUND TRUST199,7130 291,6760Abstain
Dimensional00 450,3860Abstain
Equitable314,0000 130,7690For
Allspring00 321,5560Abstain
Calamos301,6590 00For
Lord Abbett00 291,5380Abstain
Pacific Life258,0840 00For
Lincoln Financial148,9970 80,5190For
RBB FUND, INC.132,9090 94,6020For

Showing the 25 largest of 69 asset managers. See all 69 in the interactive database.

3. To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2025; and

AUDIT-RELATED

Meeting held 2025-06-10; no official results are on file for this meeting.

Combines 3 wordings of this item as funds reported it.

100% fund support · no official result

FOR 100%

The 67 asset managers below cast 100% of the shares they voted on this item FOR (47,164,283 for, 0 against).

FOR: 47,164,283 (100.0%)
Largest asset managers voting on “To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the ye” at ADAPTIVE BIOTECHNOLOGIES CORP., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard10,956,3860 00For
ARK ETF Trust7,553,9210 00For
BlackRock5,227,4590 00For
Columbia Threadneedle3,403,6100 00For
Fidelity2,838,2830 00For
Aberdeen1,640,3840 00For
MFS1,528,5960 00For
Voya1,347,9680 00For
TIAA1,265,8150 00For
ALGER FUNDS1,238,6220 00For
Bridge Builder Trust949,6010 00For
Charles Schwab926,8400 00For
Aristotle Funds Series Trust792,9750 00For
Goldman Sachs745,8530 00For
First Trust724,0910 00For
Victory Capital689,2870 00For
OPTIMUM FUND TRUST491,3890 00For
Dimensional450,3860 00For
Equitable444,7690 00For
Allspring321,5560 00For
Calamos301,6590 00For
Lord Abbett291,5380 00For
Pacific Life258,0840 00For
Lincoln Financial229,5160 00For
DRIEHAUS MUTUAL FUNDS214,8000 00For

Showing the 25 largest of 67 asset managers. See all 67 in the interactive database.

4. 14A Executive Compensation To approve, on a non-binding advisory basis, the compensation of our named executive officers as described in the proxy statement.

SECTION 14A SAY-ON-PAY VOTES

Meeting held 2025-06-10; no official results are on file for this meeting.

100% fund support · no official result

FOR 100%

The 3 asset managers below cast 100% of the shares they voted on this item FOR (921,183 for, 0 against).

FOR: 921,183 (100.0%)
Largest asset managers voting on “14A Executive Compensation To approve, on a non-binding advisory basis, the compensation of our named executiv” at ADAPTIVE BIOTECHNOLOGIES CORP., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Pier Capital, LLC671,4040 00For
RBB FUND, INC.132,9090 00For
Dunham Funds116,8700 00For

5. Advisory Vote to Ratify Named Executive Officers' Compensation

SECTION 14A SAY-ON-PAY VOTES

Meeting held 2025-06-10; no official results are on file for this meeting.

100% fund support · no official result

FOR 100%

The 3 asset managers below cast 100% of the shares they voted on this item FOR (1,235,147 for, 0 against).

FOR: 1,235,147 (100.0%)
Largest asset managers voting on “Advisory Vote to Ratify Named Executive Officers' Compensation” at ADAPTIVE BIOTECHNOLOGIES CORP., 2024-2025
Asset managerForAgainst AbstainWithheldVote
JPMorgan948,2460 00For
ESSEX INVESTMENT MANAGEMENT CO LLC267,7960 00For
FORUM FUNDS II19,1050 00For

6. To approve, on a non-binding advisory basis, the compensation of our named executive officers as described in the proxy statement.

SECTION 14A SAY-ON-PAY VOTES

Reported under meeting date 2024-06-07; no official results on file for that date (outside the 2024-2025 season's 1 July to 30 June window; reported in this season's filings).

Combines 2 wordings of this item as funds reported it.

0% fund support · no official result

AGAINST 100%

The 2 asset managers below cast 0% of the shares they voted on this item FOR (0 for, 228 against).

AGAINST: 228 (100.0%)
Largest asset managers voting on “To approve, on a non-binding advisory basis, the compensation of our named executive officers as described in ” at ADAPTIVE BIOTECHNOLOGIES CORP., 2024-2025
Asset managerForAgainst AbstainWithheldVote
COLDSTREAM CAPITAL MANAGEMENT INC0228 00Against
Echo45 Advisors LLC00 00--

7. 14A Executive Compensation

SECTION 14A SAY-ON-PAY VOTES

Meeting held 2025-06-10; no official results are on file for this meeting.

83% fund support · no official result

FOR 83%AGAINST 17%

The 2 asset managers below cast 83% of the shares they voted on this item FOR (500 for, 100 against).

FOR: 500 (83.3%)AGAINST: 100 (16.7%)
Largest asset managers voting on “14A Executive Compensation” at ADAPTIVE BIOTECHNOLOGIES CORP., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Baker Avenue Asset Management, LP5000 00For
Focus Partners Wealth0100 00Against

8. Ratify Appointment of Independent Auditors To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2025.

AUDIT-RELATED

Meeting held 2025-06-10; no official results are on file for this meeting.

100% fund support · no official result

FOR 100%

The 2 asset managers below cast 100% of the shares they voted on this item FOR (249,779 for, 0 against).

FOR: 249,779 (100.0%)
Largest asset managers voting on “Ratify Appointment of Independent Auditors To ratify the appointment of Ernst & Young LLP as our independent r” at ADAPTIVE BIOTECHNOLOGIES CORP., 2024-2025
Asset managerForAgainst AbstainWithheldVote
RBB FUND, INC.132,9090 00For
Dunham Funds116,8700 00For

Largest ADAPTIVE BIOTECHNOLOGIES CORP. shareholders voting in 2024-2025

Ranked by the number of ADAPTIVE BIOTECHNOLOGIES CORP. shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 151,916,722 shares outstanding at the time of that meeting.

Top ADAPTIVE BIOTECHNOLOGIES CORP. shareholders by shares voted, 2024-2025
#Asset manager % of shares outstanding
1VIKING GLOBAL INVESTORS LP 19.74%
2Vanguard 7.41%
3BlackRock 6.55%
4Rubric Capital Management LP 5.86%
5ARK ETF Trust 4.97%
6Nikko Asset Management Co., Ltd. 3.79%
7Columbia Threadneedle 2.24%
8Voya 2.16%
9Aberdeen 2.16%
10Fidelity 2.06%

Reported ADAPTIVE BIOTECHNOLOGIES CORP. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

ADAPTIVE BIOTECHNOLOGIES CORP. beneficial owners on record for the 2024-2025 proxy season
Holder % outstanding Disclosure
VIKING GLOBAL INVESTORS LP 19.74% 13G
Viking Global Entities 19.74% DEF14A
Rubric Capital Management LP . 9.48% DEF14A
BlackRock 8.05% 13F
Vanguard Group 7.34% 13F
Nikko Asset Management Americas, Inc. 4.50% 13G
ARK Investment Management LLC 2.90% 13G
Chad Robins 2.36% DEF14A
Millennium Management 1.97% 13F
Geode Capital 1.83% 13F

Percentages above are of 151,916,722 shares outstanding, as reported by ADAPTIVE BIOTECHNOLOGIES CORP. on its Form 10-Q dated 2025-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ADAPTIVE BIOTECHNOLOGIES CORP.’s 10-Q dated 2025-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At ADAPTIVE BIOTECHNOLOGIES CORP.'s shareholder meeting held 2025-06-10, in the 2024-2025 proxy season, 241 asset managers reported how they voted in their SEC Form N-PX filings, covering 873 separate fund positions. Their filings are grouped here into 8 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. No official Form 8-K vote tally has been matched to this meeting, so this page states no certified outcome for its most widely held ballot item. On that item — To approve, on a non-binding advisory basis, the compensation of our named executive officers… — the reporting funds cast 99% of the shares they voted in favour (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). That is the aggregate of those managers' own N-PX disclosures, not the company's certified result, and the funds are a subset of all shareholders.

ADAPTIVE BIOTECHNOLOGIES CORP. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.